Relationship Between Low‐Density Lipoprotein Cholesterol Free Proprotein Convertase Subtilisin/Kexin Type 9 and Alirocumab Levels After Different Lipid‐Lowering Strategies

摘要

BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. Every‐4‐weeks dosing of alirocumab may be appropriate for some patients in absence of background statin but is not yet approved.